The emerging role of GLP-1 receptor agonists in treating or preventing cancer
David J. Benjamin, Daniel D. Von Hoff · 2024
Read The emerging role of GLP-1 receptor agonists in treating or preventing cancer by David J. Benjamin, Daniel D. Von Hoff (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11810457.txt.
Description
David Benjamin and Daniel Von Hoff published a 2024 review of GLP-1 receptor agonists, the diabetes and weight-loss drugs, as possible cancer tools. Obesity feeds many cancers, and population data link these drugs with lower rates of obesity-related cancers in users. Lab studies add support: the drugs show antitumor activity on their own in cell and animal work.
Other preclinical studies suggest the drugs may help crack chemotherapy-resistant cancer cells. The authors argue the case is strong enough for randomized trials in both prevention and treatment. They frame the drugs as an intriguing second career for a metabolic medicine. The review is a call for proper clinical testing rather than a claim of proven benefit.
Catalog record
| CREATOR | David J. Benjamin, Daniel D. Von Hoff |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 7 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |